Combination of schizophrenia drug and radiation shows promise in treating glioblastoma – News-Medical.Net
stemadminBenefits Of Stem CellsNo comments

Reviewed by Emily Henderson, B.Sc.May 2 2020 Researchers at the UCLA Jonsson Comprehensive Cancer Center and colleagues have found that adding a drug once commonly used to treat schizophrenia to traditional radiation therapy helped improve overall survival in mice with glioblastoma, one of the deadliest and most difficult-to-treat brain tumors. The findings, published in Proceedings of the National Academy of Sciences, show that a combination of radiation and the drug trifluoperazine not only targets glioblastoma cells but also helps overcome the resistance to treatment so common to this aggressive form of cancer. The results could prove promising for patients with the disease, for whom the median survival time is only 12 to 18 months following diagnosis.

Read more
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia – BioSpace
stemadminBenefits Of Stem CellsNo comments

HOUSTON, April 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that theUnited States Food and Drug Administration(FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for the treatment of patients with acute myeloid leukemia (AML), following allogeneic stem cell transplant. "We are pleased that theFDAhas granted orphan designation to MT-401, our novel MultiTAA-specific T cell product candidate and believe it is supportive of its potential to treat post allogeneic stem cell transplant patients with AMLa devastating and pervasive blood disease with a high medical need for a treatment. In investigator-sponsored trials, our MultiTAA-specific T cell product candidate was well-tolerated and we have observed clinical benefit across various liquid and solid tumors, suggesting the product candidate's ability to induce a patient's own T cells to expand for a more durable anti-tumor effect

Read more
Sangamo ties up with a newcomer in the cell therapy field; LabCorp wins FDA authorization of latest Covid-19 test – Endpoints News
stemadminBenefits Of Stem CellsNo comments

By Jenny Gidley, Vice President, Global Clinical Operations, Alberto Grignolo, Corporate Vice President, Bridget Heelan, Vice President, Regulatory and Access Consulting Group, and Amy McKee, Vice President, Regulatory Consulting Services Parexel International COVID-19 has brought with it a number of challenges in managing ongoing clinical trials for chronic, life-threatening, and rare diseases. Enrollment is slowing or even stopping in some cases to prioritize patient safety; travel restrictions are preventing in-person patient site visits and CRA monitoring visits; regulators and industry staff who once traveled widely are working from home; some IRBs are deferring protocol review meetings, and investigator sites and hospitals are justifiably prioritizing care over clinical research activities

Read more
Stem Cell Therapy: A Promising Treatment for COVID-19? – Technology Networks
stemadminBenefits Of Stem CellsNo comments

Stem cell therapy is making its way into COVID-19 treatment. Its use seems to be particularly efficient in the case of severely ill patients, as demonstrated by a study conducted at the Beijing YouAn Hospital recently published in the peer reviewed journalAging and Disease, and as emerged after the press conference hold by Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the Ministry of Science and Technology.Bioscience Institute a company specializing in stem cell isolation, expansion and cryopreservation reported the results of the Beijing study on the diseases associated with novel coronavirus (SARSCoV-2) infection as they were anticipated before their publication

Read more

Theme: Illdy.